MAO-B is inhibited by different potent agents such as selegiline (I, Figure 1), rasagiline (II), safinamide (III), and sembragiline (IV), the most commonly used therapies for PD and Alzheimer’s disease (AD) via blocking dopamine degradation in the nigrostriatal pathway. The gene discussed is MAOB; the disease is Alzheimer disease.